KYMERA THERAPEUTICS INC's ticker is KYMR and the CUSIP is 501575104. A total of 53 filers reported holding KYMERA THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $65,872,156 | -39.5% | 4,739,004 | 0.0% | 1.78% | -41.5% |
| Q2 2023 | $108,949,702 | -22.4% | 4,739,004 | 0.0% | 3.04% | -40.8% |
| Q1 2023 | $140,416,689 | +19.9% | 4,739,004 | +1.0% | 5.13% | +3.8% |
| Q4 2022 | $117,127,396 | +14.7% | 4,692,604 | 0.0% | 4.94% | +17.1% |
| Q3 2022 | $102,158,000 | +25.4% | 4,692,604 | +13.4% | 4.22% | +7.2% |
| Q2 2022 | $81,492,000 | -46.3% | 4,138,758 | +15.4% | 3.94% | -35.2% |
| Q1 2022 | $151,787,000 | -24.8% | 3,586,658 | +12.8% | 6.07% | -17.2% |
| Q4 2021 | $201,940,000 | +8.1% | 3,180,658 | 0.0% | 7.33% | +0.6% |
| Q3 2021 | $186,832,000 | +46.4% | 3,180,658 | +20.9% | 7.29% | +52.4% |
| Q2 2021 | $127,587,000 | +24.8% | 2,630,658 | 0.0% | 4.78% | +24.8% |
| Q1 2021 | $102,227,000 | -37.3% | 2,630,658 | 0.0% | 3.83% | -40.3% |
| Q4 2020 | $163,101,000 | +91.9% | 2,630,658 | 0.0% | 6.42% | +38.6% |
| Q3 2020 | $84,997,000 | – | 2,630,658 | – | 4.63% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Atlas Venture Life Science Advisors, LLC | 5,858,262 | $81,429,842 | 12.61% |
| Aquilo Capital Management, LLC | 782,219 | $10,872,844 | 9.85% |
| BVF INC/IL | 4,739,004 | $65,872,156 | 1.78% |
| Redmile Group, LLC | 1,868,507 | $25,972,247 | 1.24% |
| Artal Group S.A. | 1,805,346 | $25,094 | 1.08% |
| Deer Management Co. LLC | 615,895 | $8,560,941 | 1.04% |
| Avoro Capital Advisors LLC | 3,855,000 | $53,584,500 | 0.84% |
| Rock Springs Capital Management LP | 1,504,351 | $20,910,479 | 0.56% |
| AtonRa Partners | 19,172 | $266,491 | 0.56% |
| Baker Brothers Advisors | 4,750,400 | $66,030,560 | 0.38% |